The U.S. Food and Drug Administration has approved Eli Lilly's once-daily oral weight-loss pill, setting the stage for a direct market confrontation with Danish rival Novo Nordisk and expanding the rapidly growing obesity drug landscape beyond the needle.
The drug, orforglipron, will be sold under the brand name Foundayo and is a once-daily oral medication targeting the GLP-1 hormone. Patients taking the drug in trials lost 12% to 15% of their body weight. Lilly said it will begin selling Foundayo on April 6 through its LillyDirect program, with broad availability through retail pharmacies and telehealth providers to follow shortly after.
The approval marks a significant milestone as the first small-molecule pill of its kind to reach approval, holding the potential to become the most accessible GLP-1 option for the millions of Americans who have not yet started treatment. The approval was fast-tracked under the FDA's new Commissioner's National Priority Voucher Program, which aims to accelerate decisions for drugs with critical public health or national security impact.
A Pill With a Competitive Edge
Unlike the Wegovy pill, which must be taken with a sip of water in the morning on an empty stomach with a 30-minute wait before eating or drinking, Foundayo can be taken at any time of day without any food or water restrictions. Lilly describes that flexibility as a significant differentiator for patients who struggle with structured dosing routines.
Data from one of the Lilly clinical trials reviewed by the FDA found that patients who took the highest dose of Foundayo for 72 weeks lost an average of 27.3 pounds, or 12.4% of their body weight, compared to 2.2 pounds for those receiving a placebo. Users also saw improvements in waist circumference, blood pressure, triglyceride levels, and cholesterol levels.
Also Read: AI Space Intelligence Platforms 2026: US vs China, Contracts, and the Arms Race
However, both the Lilly and Novo Nordisk pills resulted in less weight loss than the average achieved with injectable alternatives-Lilly's Zepbound produces 21% average weight loss, while Novo Nordisk's injectable Wegovy averages about 15%. Novo Nordisk was quick to push back on any comparisons. "Not all GLP-1s are the same. Any reports claiming orforglipron is more effective than the Wegovy pill for weight management are inaccurate and misleading," said Jamey Millar, executive vice president for U.S. operations at Novo Nordisk, adding that no head-to-head trial comparing the two pills has been conducted.
Pricing, Access, and Investor Reaction
Affordability is shaping up as a central front in the competition. The starting dose for Foundayo is $149 a month for cash-paying customers-on par with the Wegovy pill's entry price-but Foundayo is cheaper at higher doses. Lilly also said that if patients refill their prescription within a 45-day window, the highest out-of-pocket price would be $299 a month. Eligible patients with commercial insurance may pay as little as $25 per month with a Lilly savings card, while eligible Medicare Part D individuals may access Foundayo for $50 per month beginning July 1, 2026.
"As a convenient, once-daily oral pill that delivers meaningful weight loss, this is obesity care designed for the real world," said Lilly CEO David Ricks. Ricks also noted that fewer than one in ten people who could benefit from a GLP-1 therapy are currently taking one, held back by access barriers, stigma, and the complexity of existing treatment options.
Markets responded positively to the news. Shares of Eli Lilly rose more than 4% in trading on Wednesday afternoon. Analysts estimate Foundayo sales will reach $14.79 billion by 2030, according to FactSet, compared with $24.68 billion projected for Zepbound and $44.87 billion for Mounjaro. As reported by Reuters, oral weight-loss drugs are not expected to fully replace injectables, but analysts estimate pills could capture around 20% of the market by 2030.
Safety Profile and Global Ambitions
Foundayo's label carries a boxed warning-the FDA's most serious label addition-advising of an increased risk of thyroid C-cell tumors, a warning that also appears on Novo's oral and injectable Wegovy. The most common side effects reported in trials were nausea, constipation, diarrhea, and vomiting. Between 5% and 10% of participants discontinued treatment due to gastrointestinal issues, compared with nearly 3% in the placebo group.
Lilly has submitted orforglipron for approval in more than 40 countries and plans to launch in each market shortly after regulatory clearance. Beyond weight management, the drug is also being studied as a potential treatment for type 2 diabetes, obstructive sleep apnea, osteoarthritis knee pain, and hypertension, potentially broadening its commercial footprint well beyond the obesity market.
Foundayo's entry into pharmacies next week marks the beginning of what analysts expect to be an intensifying global competition between the two obesity drug giants, with pricing, convenience, and insurance coverage likely to determine which pill gains the larger patient base in the months ahead.
